Hypophosphatemic rickets developed after treatment with etidronate disodium in a patient with generalized arterial calcification in infancy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 28377967.
- Also identified by DOI 10.1016/j.bonr.2015.09.001 and PMC identifier 5365274.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Ectonucleotide pyrophosphatase/phosphodiesterase 1 (<i>ENPP1</i>) was originally reported as a responsible gene for generalized arterial calcification in infancy (GACI). Though the prognosis of GACI patients is poor because of myocardial infarction and heart failure in relation to medial calcification of the coronary arteries, some patients rescued by bisphosphonate treatment have been reported. Recently, <i>ENPP1</i> is also reported as responsible for autosomal recessive hypophosphatemic rickets type 2. We show here a boy with homozygous <i>ENPP1</i> mutations diagnosed as having GACI in early infancy. After the diagnosis, he was treated with etidronate disodium (EHDP) in combination with antihypertensive drugs. The calcification of major arteries was diminished and disappeared by the age of eight months. He also showed mild hypophosphatemia (2.6-3.7 mg/dl) from the age of one year. After the treatment with EHDP for five years, he showed genu valgum with hypophosphatemia (2.6 mg/dl). He was diagnosed as having hypophosphatemic rickets at the age of seven years. The findings that hyper-mineralization of the arteries and hypo-mineralization of the bone observed in the same patient are noteworthy. <i>ENPP1</i> could be regarded as a controller of the calcification of the whole body at least in part.